HEALTH LAW

Whether you are a clinical practice creating new legal procedures for emerging technologies or an individual considering options like dementia testing, the legal landscape can be complex, fast-moving, and deeply consequential. Clear, practical guidance is essential to move forward with making a meaningful decision for you.

BioLaw Group brings a distinctive blend of legal and bioethics experience to this work. BioLaw Group advises medical practices, researchers, and individuals on legal issues at the forefront of healthcare, including genomic testing, reproductive care, emerging clinical applications, biomarkers for diagnosing dementia, and medical aid in dying. We help providers integrate new tools and treatments into their practices in a compliant and sustainable way, while also helping individuals and families understand their rights, options, and risks when making deeply personal healthcare decisions. This depth allows BioLaw Group to navigate sensitive, evolving areas with both technical precision and ethical insight.

Our approach is grounded in both legal experience and bioethics, ensuring that advice is not only legally sound but aligned with patient care and human impact. BioLaw Group works alongside clients to translate complex science into clear choices—supporting responsible innovation for providers and informed decision-making for the people they serve. Operating at the leading edge, BioLaw Group develops innovative legal strategies that bridge discovery and application—helping transform emerging technologies into meaningful, lawful improvements in everyday life. We partner with clients to anticipate risk, ensure compliance, and responsibly advance innovation in ways that serve patients, providers, and communities.

Peer Reviewed Published Articles

“Constitutional and Family Law Parameters” chapter in Disputed Paternity Proceedings, Mathew
Bender (December, 2003).

“Who is the Parent? Weighing Genetics, Gestation and Intent,” 25 Family Advocate 6 (2) (Fall,
2002).

“Impact of Genetic Privacy Legislation on Insurer Behavior,” 4 Genetic Testing (1) 31 (2000) (with
William Mulholland).

“Meeting the Needs of Children of Assisted Conception,” 14 American Journal of Family Law (1)
44 (Spring, 2000).

“Genetic Privacy and Discrimination: A Survey of State Legislation,” 39 Jurimetrics 317 (1999).

“Health Insurance and People with Psychiatric Disabilities,” in Psychiatric Disabilities, Employment and
the Americans With Disabilities Act, U.S. Congress, Office of Technology Assessment (March 1994).

“Confidentiality of Genetic Information in the Workplace,” 17 American Journal of Law and Medicine (1
& 2) 75 (with Lori B. Andrews) (1991).

Expanded preconception carrier screening in clinical practice: cutting the Gordian Knot. Lindheim SR, Jaeger AS. Fertil Steril. 2015 Aug;104(2):281-2. doi: 10.1016/j.fertnstert.2015.06.016. Epub
2015 Jun 27. PMID: 26123444

Inform and consent: more than just “sign here”. Madeira JL, Coyne K, Jaeger AS, Parry JP, Lindheim SR. Fertil Steril. 2017 Jul;108(1):40-41. doi: 10.1016/j.fertnstert.2017.03.022. Epub 2017 Apr 20. PMID: 28434753

Needs assessment for those donating to stem cell research. Zweifel J, Christianson M, Jaeger AS, Olive D, Lindheim SR. Fertil Steril. 2007 Sep;88(3):560-4. doi: 10.1016/j.fertnstert.2006.12.042. Epub 2007 Jun 4. PMID: 17544415 Free article.

Decisions to donate surplus embryos. Lindheim SR, Jaeger AS, Zweifel JE. Fertil Steril. 2008 Aug;90(2):469-70; author reply 470. doi: 10.1016/j.fertnstert.2008.05.082. Epub 2008 Jul 3. PMID: 18599049

Attitudes and opinions towards genetic testing among US Hispanics. Jaeger AS, Goode EL, Boyle JM. Am J Hum Genet. 1997 Oct;61(4):A221. PMID: 1164496

Survey report of gamete donors’ and recipients’ preferences regarding disclosure of third party reproduction outcomes and genetic risk information. Lindheim SR, Porat N, Jaeger AS. J Obstet Gynaecol Res. 2011 Apr;37(4):292-9. doi: 10.1111/j.1447-
0756.2010.01333.x. Epub 2011 Feb 23.